Teva Pharmaceutical Industries Limited
TEVA
$33.92
-$0.39-1.14%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 321.20% | 199.08% | 133.33% | 253.96% | -146.87% |
| Total Depreciation and Amortization | -3.35% | -3.86% | -3.09% | -10.29% | 1.13% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -75.39% | -55.23% | -95.71% | -42.92% | 371.17% |
| Change in Net Operating Assets | 193.47% | -276.97% | -3,260.00% | -40.85% | -183.90% |
| Cash from Operations | 101.39% | -46.75% | 120.39% | 15.32% | -51.44% |
| Capital Expenditure | -10.08% | 8.11% | 1.03% | -2.42% | -8.40% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -100.00% | -78.95% | 800.00% | -- | -- |
| Other Investing Activities | -6.12% | -30.42% | 17.88% | 9.89% | -22.14% |
| Cash from Investing | -18.32% | -49.63% | 32.58% | 39.58% | -32.89% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 100.00% | -- | -140.59% | -- | -37.00% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 263.64% | -- | 110.00% | -149.01% | 114.47% |
| Cash from Financing | 105.93% | -- | 100.62% | -1,054.97% | -17.01% |
| Foreign Exchange rate Adjustments | 91.74% | -109.00% | 89.80% | 143.27% | -277.94% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 7,616.67% | -96.04% | 163.30% | -579.24% | -101.84% |